Assess whether biosimilarity is analytically justified (13d09e)

Situation

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — CMC comparability package for a site change — after a literature paper the 505(b)(2) package leans on getting retracted. If CMC comparability package for a site change cannot support biosimilarity is analytically justified, the honest Pharma & Life Sciences output is hold.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• A literature paper the 505(b)(2) package leans on getting retracted is noise around an already-controlled CMC and Development Pathways process in an RWE group proposing a post-marketing study instead of a new RCT, given CMC comparability package for a site change.
• A literature paper the 505(b)(2) package leans on getting retracted is the event in CMC comparability package for a site change that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences.
• CMC comparability package for a site change shows a one-file miss after a literature paper the 505(b)(2) package leans on getting retracted, not a CMC and Development Pathways program failure.
• CMC comparability package for a site change cannot decide biosimilarity is analytically justified yet after a literature paper the 505(b)(2) package leans on getting retracted; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move biosimilarity is analytically justified for clinical-development physician.